Skip to main content

Table 1 Cell viability in MCF-7 and SK-Br-3 cells

From: The in vitro influences of epidermal growth factor and heregulin-β1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinoma

  MCF-7 SK-Br-3
Trastuzumab (50 μg/ml) 95.35% (± 2.27) 72.58% (± 1.31)
(EGF + T 50 : P < 0.001)
EGF (400 ηg/ml) 101.70% (± 1.84) 81.43% (± 2.46)
(EGF + T 50 : P < 0.001)
EGF (400 ηg/ml) + Trastuzumab (50 μg/ml) 89.52% (± 1.95) 89.40% (± 2.20)
  (Trastuzumab 50 : P < 0.05)
HRG (200 ηg/ml) 107.01% (± 2.42) 115.40% (± 2.08)
(Trastuzumab 50 : P < 0.001) (Trastuzumab 50 : P < 0.001)
HRG (200 ηg/ml) + Trastuzumab (50 μg/ml) 93.76% (±2.52) 114.50% (± 1.98)
  (HRG: P < 0.001) (Trastuzumab 50 : P < 0.001)
  1. Mean (± SEM) cell viability determined using a tetrazolium conversion assay.